Tidepool Loop and Future Diabetes Care?

Opinions

Date: 17.02.2021

GlobalData projects that innovation in digital platforms and devices will be critical for long-term type 1 diabetes management and that the app format of Tidepool Loop will be a gamechanger for AID systems.

At the beginning of 2021, Tidepool announced the 510(k) submission of Tidepool Loop to the Food and Drug Administration (FDA). Tidepool, a 501(c)(3) non-profit organisation focused on accessible, actionable, and meaningful diabetes data, is one of the few companies in the FDA’s Digital Health Software Precertification Pilot Program, and Tidepool Loop would be the first app approved by the FDA to work as a part of an automated insulin delivery / dosing (AID) system or ‘artificial pancreas’.

GlobalData projects that innovation in digital platforms and devices will be critical for long-term type 1 diabetes (T1D) management and that the app format of Tidepool Loop will be a gamechanger for AID systems and achieving glycemic control.

While the potential for a disease-modifying therapeutic or ‘cure’ for type 1 diabetes is uncertain, key opinion leaders (KOLs) interviewed by GlobalData have been staunch in their belief that the future of T1D management is continuous glucose monitoring (CGM), and ultimately, an AID solution.

The article was prepared based on the information: MedicAldevice 

Views: 15

Leave a request

Select option
Thank you, application submitted.